Former insider hits out at FDAs links with pharmaceutical industry

A former senior consultant with the Food and Drug Administration (FDA) has criticised the American regulator's close relationship with the pharmaceutical industry. Interviewed in this week's BMJ, he attacks the FDA's decision to allow the re-marketing of a controversial drug.

Dr Paul Stolley joined the FDA in July 2000 to look into the post-marketing safety of alosteron (Lotronex), a treatment for irritable bowel syndrome manufactured by GlaxoSmithKline. Within months he was writing to his superiors about a rising toll of adverse incidents, including ischaemic colitis, hospitalisation, surgery, and deaths.

Glaxo Wellcome (as the company was then) voluntarily withdrew alosteron in November 2000, but almost immediately patient groups were pushing for its return. Stolley claims that his superior, Dr Janet Woodcock, accused him of "brow-beating" colleagues about the drug's risks. He also says other colleagues concerned about the drug's safety were pressurised to "help get this drug back on the market". Woodcock, however, says that alosetron is an example of how difficult it is to provide access to a risky drug for those in greatest need. On Stolley himself she says: "It's our responsibility to be dispassionate and not develop emotionally based positions".

In April a special advisory committee recommended that alosetron be remarketed on the condition that it was prescribed only by specially certified doctors. Six weeks later, however, the FDA formally re-approved marketing based only on "physician self attestation of qualifications".

A number of the committee members are now publicly warning of a risk of more deaths and another withdrawal if the drug returns to the market later this year. What happens in America is likely to determine whether the company pursues approval for the drug elsewhere in the world.

Over the last ten years eight drugs have been approved by the FDA and subsequently withdrawn for safety reasons, pro

Contact: Steve Harman
BMJ-British Medical Journal

Page: 1 2

Related medicine news :

1. Former President George Bush joins leaders from cancer community to announce historic collaboration
2. Former NHLBI director Lenfant receives Lifetime Achievement Award
3. How links with tobacco industry may have influenced the publication of research on second-hand smoke
4. Study links racial and ethnic gap in youth violence to social factors
5. Study links sexual behavior, genetic factors to increased risk of kidney infection in women under 50
6. New UCLA study develops links between socioeconomic status and poor health
7. New study links lead exposure with increased risk of cataract
8. Leading tobacco manufacturer conceals links to tobacco research facility
9. New analysis links breastfeeding to reduced risk of childhood leukemia
10. Study links warm offices to fewer typing errors and higher productivity
11. UMHS study links gonorrhea, prostate cancer in men

Post Your Comments:

(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest ... its plans to open a flagship location in Covington, LA at 401 N. U.S. ... Go store next to Office Depot in the Holiday Square shopping center. Its location ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology:
Cached News: